Results 91 to 100 of about 1,148,675 (153)

Biosimilars for Haematologic Malignancies: The Path to Sustainable Care

, 2017
The main objectives of this symposium were to review the value of biosimilars in sustainable treatment for haematologic malignancies and to recognise the developmental differences between biosimilars and their reference products.
Paul Cornes, Arnold G. Vulto, Wojciech Jurczak   +2 more
core  

Dual-Capped Helical Interface Mimics

Disruption of protein–protein interactions is medicinally important. Interface helices may be mimicked in helical probes featuring enhanced rigidities, binding to protein targets, stabilities in serum, and cell uptake.
Kevin Burgess (531564), Tianxiong Mi (13388631), Zhe Gao (1537531), Zeynep Mituta (18308602)   +3 more
core   +1 more source

A Dual Egalitarian Solution [PDF]

In this note we introduce an egalitarian solution, called the dual egalitarian solution, that is the natural counterpart of the egalitarian solution of Dutta and Ray (1989).We prove, among others, that for a convex game the egalitarian solution coincides
Tijs, S.H., Slikker, M., Klijn, F.
core  

Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies. [PDF]

Biofactors
Su K, Tan Z, Li H, You K, Xiao S, Chen H, Li D, Liu X, Du X, Hu J, He K, Xu Y, Chen J, Han Y.   +13 more
europepmc   +1 more source

Dual targeting of PDPN and GD2 enhances CAR T cell efficacy against glioblastoma and promotes durable tumor control. [PDF]

Mol Ther Oncol
Hübner J, Nerreter T.
europepmc   +1 more source

Judicious utilisation of surgical and advanced radiotherapy resources to manage triple trouble: a case of synchronous dual malignancies with severe cervical spine deformity. [PDF]

BMJ Case Rep, 2018
Ahmad I, Lohan R, Chufal KS, Raina S.
europepmc   +1 more source

Editorial: Chimeric antigen receptor T cell therapies and bispecific antibodies in hematologic malignancies. [PDF]

Front Oncol
Zhu Y.
europepmc   +1 more source

Next-Generation Immune Checkpoint Inhibitors in Gastrointestinal Cancers: Mechanisms, Resistance, and Emerging Therapeutic Strategies. [PDF]

Cancers (Basel)
Ismail M, Alabed Z, Alhallaq K, Al-Najjar E, Mustafa N, Aldroubi Y, Hamdaneh Y, Esmail A.   +7 more
europepmc   +1 more source

Editorial: Emerging targeted and immunotherapeutic strategies in oncology: from solid tumors to hematologic malignancies. [PDF]

Front Pharmacol
Muresan XM, Tigu AB, Roman A, Romani A.
europepmc   +1 more source

Dual Immune Checkpoint Blockade in Synchronous Hepatocellular and Renal Cell Carcinoma: A Real-World Case Report of Durable Dual Response. [PDF]

Oncol Res
Federico P, Canciello MA, Granata B, Bosso D, Daniele B.   +4 more
europepmc   +1 more source